An artificial intelligence (AI) device that has been fast-tracked for approval by the Food and Drug Administration may help identify newborns at risk for aggressive posterior retinopathy of prematurity (AP-ROP). AP-ROP is the most severe form of ROP and can be difficult to diagnose in time to save vision. The findings of the National Eye Institute-funded study published online February 7 in Ophthalmology.
“Artificial intelligence has the potential to help us recognize babies with AP-ROP earlier. But it also provides the foundation for quantitative metrics to help us better understand AP-ROP pathophysiology, which is key for improving how we manage it,” said the study’s lead investigator, J. Peter Campbell, M.D., M.P.H., Casey Eye Institute, Oregon Health and Science University in Portland.
Babies born prematurely are at risk for retinopathy. That is, they have fragile vessels in their eyes, which can leak blood and grow abnormally. If left untreated, vessel growth can worsen and cause scarring, which can pull on and cause detachment of the retina, the light-sensing tissue at the back of the eye. Retinal detachment is the main cause of vision loss from ROP. Each year, the incidence of ROP in the United States is approximately 0.17%. Most cases are mild and resolve without treatment.
Upon birth, the eyes of preemies are screened and closely watched for signs of retinopathy. But ROP-related changes occur along a spectrum of severity. AP-ROP can elude diagnosis because its features can be more subtle and harder to appreciate than typical ROP. AP-ROP was formally recognized as a diagnostic entity in 2005. Yet in everyday practice there’s significant variation in how clinicians interpret whether fundus images taken of the inside of the eye show signs of AP-ROP. “Even the most highly experienced evaluators have been known to disagree about whether fundus images indicate AP-ROP,” said Campbell.
In a previous study, deep learning, a type of AI used for image recognition, was more accurate than experts at detecting subtle patterns in fundus images and at classifying ROP. Using the automated deep learning ROP classifier, researchers devised a quantitative vascular severity score (1-9 scale) for evaluating newborns, monitoring disease progression and response to treatment. The study, however, did not specifically address AP-ROP detection.
For the current study, nine neonatal care centers used deep learning to determine how well it detected AP-ROP. The 947 newborns in the study were followed over time and fundus images from a total of 5945 eye examinations were analyzed both by the deep learning system and a team of expert fundus image graders.
Among all eyes followed, 3% developed AP-ROP.
There was a significant level of inter-reader disagreement among the expert graders, suggesting the need for objective metrics of disease severity.
Importantly, a clearer, quantifiable AP-ROP patient profile emerged, which could help identify at-risk infants earlier. Infants who developed AP-ROP tended to be more premature. Compared with infants who needed treatment but never developed AP-ROP-, AP-ROP infants were born lighter (617 g vs. 679 g) and younger (24.3 weeks vs. 25.0 weeks). No infants born after 26 weeks developed AP-ROP in this population.
AP-ROP also tended to onset rapidly and quickly grow worse. Although rapid progression of disease has always been implied in the diagnosis of AP-ROP, to date there has been no way to measure this clinical feature. Monitoring the rate of vascular severity score changes could therefore improve detection of AP-ROP risk, according to the study findings.
Infants with AP-ROP also were more likely to have comorbidities such as chronic lung disease, compared to infants without AP-ROP. The requirement for higher oxygen concentrations among infants with lung disease may have played a role in their eye disease, said Campbell. Decades ago, researchers made a connection between the routine use of high concentrations of oxygen at birth and an increase in the development of retinopathy. Oxygen is nearly always required for survival, but is titrated very carefully to maximize survival while minimizing the risk to vision. “It’s still a balancing act,” said Campbell.
“It’s important to acknowledge that there is currently no gold standard for diagnosing AP-ROP. But having objective, AI-based metrics for detecting AP-ROP is a step in the right direction for this highly vulnerable population of infants,” said Grace L. Shen, Ph.D., who manages the retinal diseases program for the Division of Extramural Science Programs at the NEI.
The deep learning system in the clinical trial, the i-ROP DL system, was recently granted breakthrough status by the FDA, which accelerates its development and FDA review. Development of the device was supported by the NEI, part of the National Institutes of Health.
Funding for the study was provided by grants R01EY19474, K12EY027720, T15LM007088, and P30EY10572.
Bellsmith KN, Brown J, Kim SJ, Goldstein IH, Coyner A, Ostmo S, Gupta K, Chan RVP, Kalpathy-Cramer J, Chiang MF, Campbell JP, “Aggressive Posterior Retinopathy of Prematurity: Clinical and Quantitative Imaging Features in a Large North American Cohort”. Published online February 7, 2020. Ophthalmology. https://doi.org/10.1016/j.ophtha.2020.01.052
NEI leads the federal government’s research on the visual system and eye diseases. NEI supports basic and clinical science programs to develop sight-saving treatments and address special needs of people with vision loss. For more information, visit https://www.nei.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit https://www.nih.gov/.
NIH…Turning Discovery Into Health®